New York (March 2nd, 2013) - MannKind Corp. (NASDAQ: MNKD) announced that it will present at the Cowen and Company 33rd Annual Health Care Conference on March 5, 2013 at 10:40 AM (EST) at the Boston Marriott Copley in Boston, Massachusetts.
MannKind Corporation, a development stage biopharmaceutical company. MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Opko Health, Inc. (NYSE: OPK) announced that a study published online in Clinical Chemistry, and to be included in the April 2013 print issue, describes the application of OPKO’s point-of-care system to mobile diagnostics, a major advance towards providing people in resource poor settings with laboratory-quality diagnostic services and directly integrating results with cloud-based patient records.
In collaboration with OPKO, Samuel Sia, associate Professor of Biomedical Engineering at Columbia Engineering and cofounder of Claros Diagnostics (now OPKO Diagnostics), has demonstrated that their lab-on-a-chip technology can be used not only to check a patient’s infectious disease status anywhere in the world with just a finger prick, but also synchronize the results automatically and instantaneously with central health-care records.